Strong Competitive Position Drove Haemonetics Corporation’s (HAE) Earnings Growth

2 weeks ago 9

Soumya Eswaran

Mon, February 16, 2026 astatine 8:16 AM CST 3 min read

Aristotle Capital Boston, LLC, an concern advisor, released its fourth-quarter capitalist missive for “Small Cap Equity Fund”. A transcript of the missive tin beryllium downloaded here. U.S. small-cap equities reported humble gains successful the 4th fourth of 2025. The 4th started arsenic a continuation of the post-Liberation Day risk-on marketplace environment, portion it ended connected a beardown note, driven by a affirmative macroeconomic backdrop. Attractive valuations, net recovery, broadening of the market, and a displacement from mega-cap stocks supported tiny caps successful the quarter. The Aristotle Small Cap Equity Fund (Class I-2) returned 1.96% successful Q4 2025, trailing the 2.19% full instrumentality of the Russell 2000 Index. Security enactment supported wide performance, portion allocation effects detracted from performance. Please reappraisal the Strategy’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, Aristotle Small Cap Equity Fund highlighted Haemonetics Corporation (NYSE:HAE) arsenic 1 of its starring contributors. Haemonetics Corporation (NYSE:HAE) is an innovative aesculapian exertion institution that provides solutions for improving diligent care. On February 13, 2026, Haemonetics Corporation (NYSE:HAE) banal closed astatine $57.76 per share. One-month instrumentality of Haemonetics Corporation (NYSE:HAE) was -19.97%, and its shares are down 7.38% implicit the past 12 months. Haemonetics Corporation (NYSE:HAE) has a marketplace capitalization of astir $2.68 billion.

Aristotle Small Cap Equity Fund stated the pursuing regarding Haemonetics Corporation (NYSE:HAE) successful its 4th fourth 2025 capitalist letter:

"Haemonetics Corporation (NYSE:HAE) is simply a planetary supplier of hematology and humor absorption products and solutions. The institution reported beardown earnings, beating expert expectations. We judge that the company’s beardown competitory presumption wrong the plasmapheresis marketplace on with accrued concern successful probe and improvement should make worth for shareholders implicit a multi-year period."

Is Haemonetics Corporation (HAE) the Best Russell 2000 Stock to Buy According to Wall Street Analysts?

Haemonetics Corporation (NYSE:HAE) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 36 hedge money portfolios held Haemonetics Corporation (NYSE:HAE) astatine the extremity of the 3rd quarter, which was 29 successful the erstwhile quarter. Haemonetics Corporation (NYSE:HAE) reported third-quarter gross was $339 million, bringing year-to-date gross to $988 million. While we admit the imaginable of Haemonetics Corporation (NYSE:HAE) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article